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Abstract
Background: Integrated Palliative Care (PC) strategies are often implemented following models, namely standardized
designs that provide frameworks for the organization of care for people with a progressive life-threatening illness
and/or for their (in)formal caregivers. The aim of this qualitative systematic review is to identify empirically-evaluated
models of PC in cancer and chronic disease in Europe. Further, develop a generic framework that will consist of the
basis for the design of future models for integrated PC in Europe.
Methods: Cochrane, PubMed, EMBASE, CINAHL, AMED, BNI, Web of Science, NHS Evidence. Five journals and
references from included studies were hand-searched. Two reviewers screened the search results. Studies with
adult patients with advanced cancer/chronic disease from 1995 to 2013 in Europe, in English, French, German,
Dutch, Hungarian or Spanish were included. A narrative synthesis was used.
Results: 14 studies were included, 7 models for chronic disease, 4 for integrated care in oncology, 2 for both
cancer and chronic disease and 2 for end-of-life pathways. The results show a strong agreement on the benefits
of the involvement of a PC multidisciplinary team: better symptom control, less caregiver burden, improvement
in continuity and coordination of care, fewer admissions, cost effectiveness and patients dying in their preferred place.
Conclusion: Based on our findings, a generic framework for integrated PC in cancer and chronic disease is proposed.
This framework fosters integration of PC in the disease trajectory concurrently with treatment and identifies
the importance of employing a PC-trained multidisciplinary team with a threefold focus: treatment, consulting
and training.
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Background
According to the World Health Organization (WHO),
Palliative Care (PC) aims to improve the quality of life of
patients and families who face life-threatening illness, by
providing pain and symptom relief, spiritual and psycho-
social support from diagnosis to end of life care and
bereavement. Further, the WHO recommends that PC
becomes an integral part of health care and that all
patients affected by a life threatening disease should
have access to PC services [1]. This statement is further
supported by the European Association of Palliative Care
[2] and is also in agreement with the guidelines of the
European Council towards the European Union (EU)
Member States [3].
This consensus in favour of integrating PC within regu-
lar treatment offered to patients with life-threatening dis-
ease is supported by a growing amount of evidence that
indicates the effectiveness of PC on the improvement of
the quality of life of these patients [4–8].
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The implementation of integrated PC strategies is often
based on models. Models of care are standardized designs
that provide frameworks for the organization of care for
people with a progressive life-threatening illness and/or
for their (in)formal caregivers. As such, models deter-
mine the norms of PC practice and offer values and
principles that professionals can use as guides and can
thus provide important information for understanding
integrated PC practices and evaluating their associated
strengths and weaknesses.
To date, a univocally accepted model for PC delivery
and integration does not exist, even if we confine our-
selves to cancer or a major chronic disease. However,
there are calls for developing generic PC models that
will incorporate recent findings concerning the early
identification of patients with needs for PC services and
foster the integration of PC early in the care plan and
throughout the disease trajectory [9–15].
In the present study, we perform a qualitative system-
atic review of the available literature for evidence-based
models of integrated PC in Europe. We confine ourselves
to studies that empirically measure the effectiveness of the
corresponding models and employ a high-quality meth-
odological rigour. Further, we examine the conformance
of the included studies with respect to how the character-
istics and requirements of integrated PC and strengths
and weaknesses are documented. By incorporating the
strengths and by rectifying the weaknesses, we propose a
generic framework that aspires to demonstrate how to in-
tegrate PC both in cancer and chronic disease. This study
is part of the European project InSup-C that focuses on
integration of PC in advanced cancer and chronic disease
in Europe (http://www.insup-c.eu/).
Methods
A unanimously agreed definition of integrated PC does
not exist as such. For the needs of the present study, a
novel definition was developed in the course of the
InSup-C meetings by the PC experts and the authors.
This definition combines all the aspects of integrated
PC, identified by both experts and literature. Our
working definition is: “Integrated palliative care involves
bringing together administrative, organisational, clinical
and service aspects in order to realise continuity of care
between all actors involved in the care network of pa-
tients receiving palliative care. It aims to achieve quality
of life and a well-supported dying process for the patient
and the family in collaboration with all the care givers
(paid and unpaid)”.
It is important to note that this definition does not
distinguish between timings that integration of PC can
commence. Consequently, both early and end-of-life PC
care can be part of this review.
Finally, this qualitative systematic review was con-
ducted in Belgium in September of 2013.
Selection criteria
Eligible studies included those focusing on models of in-
tegrated PC for adult patients with cancer or another
chronic disease (COPD, renal failure, heart failure, HIV,
dementia or other types of neurological diseases), that
are, in turn, consistent with the above-mentioned defini-
tions of models and of integrated PC. Since our primary
objective concerns the identification of evidence based
models, only those studies that empirically assessed the
effectiveness of these models and provided relevant data
were considered eligible. In particular, we considered
randomized controlled trials (RCTs), quasi experimental
studies, cohort studies, controlled before-and-after stud-
ies, observational studies and pilot evaluation studies
whereas we excluded theoretical studies, audits, opinion-
only studies in clinical case reports, editorials and letter.
We confided ourselves to studies published from 01-01-
1995 (based on the publication year of the Calman-Hine
report which constitutes the first national cancer plan in
Europe [16]) to 31-12-2013 in one of the following
languages: English, French, German, Dutch, Hungarian
and Spanish which are the languages that the authors
were knowledgeable of.
A final eligibility criterion concerned the quality of the
included studies with respect to the methodological
rigor. In the present systematic review, only studies that
that scored at least 60 % (above 22/36) in the Hawker
quality assessment scale were included in this systematic
review; see Quality assessment section below.
Search strategy
The following databases were searched electronically:
The Cochrane Central Register of Controlled Trials
(CENTRAL), PubMed, EMBASE, CINAHL, AMED,
BNI, Web of Science and NHS Evidence. The search
in the databases was performed via the use of keywords,
MESH terms and search terms as well as their permuta-
tions and combinations. The basic search terms and
keywords that were used in PubMed and similarly in the
other electronic databases are presented in Appendix.
Validation of the search strategy was performed against
five key papers [4–8].
Additionally, the following journals were hand-searched:
BMJ Supportive & Palliative Care, European Journal of
Palliative Care, Journal of Pain and Symptom Manage-
ment, Palliative Medicine and Medicina Paliativa. Citation
tracking was also performed for the included studies.
Two different grey literature searches were performed.
First, we identified and contacted experts in national
scientific medical organizations in order to acquire
additional information on existing models. Second, we
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carried out an electronic search in Google by utilizing a
language-tailored strategy; more specifically, each coun-
try used relevant key-words and search terms translated
into its corresponding language.
Selection procedure
In the first phase, two reviewers (NS & KVB) screened all
the search results on the basis of their title and their ab-
stract. Non-English titles were screened and translated by
two native speaker reviewers. The full texts of articles se-
lected by both reviewers were sourced. Following standard
practice, discrepancies were resolved by consensus.
Data extraction
Data were extracted from papers meeting the inclusion
criteria using an extraction form built upon the one de-
scribed in Hawker et.al. This extraction form was modi-
fied for the purposes of this study following consensus
in the InSup-C project meetings [17]. For each included
paper, data extraction was carried out by the first two
authors independently for the cross-checked their results
and reached consensus on discrepancies. Extracted vari-
ableswere: first author’sname, year of the study, country the
study was conducted, design, quality assessment, descrip-
tionof the studymodel, outcomemeasures, results, focus of
themodel, setting, time frame of themodel, disciplines rep-
resentedandcollaborationstrategy.
Quality assessment
The methodological rigour of each included study was
formally assessed by the numerical scoring system
designed by Hawker et al. [17]. This scoring system is
based on nine criteria that are evaluated with a four-
point Likert scale: good (4) to very poor (1), thus yield-
ing a maximum score of 36. The nine criteria are:
abstract/title, introduction/aims, methods/data, sam-
pling, data analysis, ethics and bias, findings/results,
transferability/generalizability, implications/usefulness. It
is important to note that the criterion corresponding to
methods takes into account the design of the study as
well, e.g. RCT, observational study etc. It is on this
premise that in the present systematic review we have
included studies with different designs and not only
RCTs. A detailed presentation of the Hawker tool is re-
ported in Table 1. Our choice is also influenced by Oishi
et al. and Rigby et al. who used the Hawker tool while
conducting a PC-related systematic review [18, 19].
Data synthesis
The included studies were characterized by a substantial
heterogeneity as studies with both clinical and methodo-
logical diversities were included. For this reason, a nar-
rative synthesis was favoured over a meta-analysis and
data are reported in tables; hence the qualitative
nature of the review mentioned above. This hetero-
geneity has also affected the presentation of the re-
sults. Comparative analysis was only possible by using
a specific number of categories (design, study popula-
tions, assessments and outcomes) that will be pre-
sented in the following sections.
Results
The database search returned 28,274 hits, excluding
duplicates. From the studies that were screened based
on abstract/title, 1989 were found to be eligible for
full-text screening. Upon full text screening, 491
studies qualified for further assessment of their eligi-
bility. Finally, 14 studies were found to comply with
all the selection criteria (see relevant section above).
The grey literature search did not add any empirical
studies. A flow diagram of the selection procedure and the
results is shown in Fig. 1.
From the 14 studies, 7 evaluated models about
chronic disease (dementia, multiple sclerosis, chronic
heart failure, HIV/AIDS and advanced chronic disease in
general), 4 about integrated care in oncology, 3 about can-
cer and chronic disease (end-of-life patients). The majority
of the included studies were from the UK (6 out of 14), 2
were from Spain, 2 from The Netherlands, and one each
from Italy, Germany, Norway and France. The preponder-
ance of UK studies is clear in chronic disease where all 6
included studies were from this nation.
The 14 included studies were built upon quite differ-
ent designs (Table 2) [20–33]. More specifically, there
were 6 RCTs, 2 observational studies, 2 cohort studies, 2
pilot evaluation studies, 1 uncontrolled before-and-after
studies and 1 quasi-experimental study.
Table 2 provides information concerning the quality
of the included studies, as measured via the Hawker et
al. tool. Two (2) studies [29, 30] scored a perfect 36
while 3 other studies scored 33 or 34. The majority of
the remaining studies scored in the range between 23
and 31. Table 2 includes detailed information concern-
ing the models of the included studies, their outcome
measures and the results/effectiveness of the corre-
sponding models. From this table, we can infer that al-
though RCTs tend to score higher and observational
studies lower, other designs perform reasonably well.
The latter indicates that such studies have a sound
basis, despite the fact that they do not employ an RCT
for their assessment.
Even though some of the models bear similarities, (see
Table 3 Screening), differences associated with the care
setting and the compositions of the team render further
grouping and comparison difficult. Upon detailed exam-
ination, a common ground for comparison was found in
the following categories: focus of intervention, the set-
ting, the timing of the intervention in the disease
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Table 1 Hawker tool description
1. Abstract and title: Did they provide a clear description of the study?
Good Structured abstract with full information and clear title.
Fair Abstract with most of the information.
Poor Inadequate abstract.
Very poor No abstract.
2. Introduction and aims: Was there a good background and clear
statement of the aims of the research?
Good Full but concise background to discussion/study
containing up-todate literature review and highlighting
gaps in knowledge.
Clear statement of aim AND objectives including
research questions.
Fair Some background and literature review.
Research questions outlined.
Poor Some background but no aim/objectives/questions, OR
Aims/objectives but inadequate background.
Very poor No mention of aims/objectives.
No background or literature review.
3. Method and data: Is the method appropriate and clearly explained?
Good Method is appropriate and described clearly
(e.g., questionnaires included). Clear details of
the data collection and recording.
Fair Method appropriate, description could be better.
Data described.
Poor Questionable whether method is appropriate.
Method described inadequately.
Little description of data.
Very poor No mention of method, AND/OR
Method inappropriate, AND/OR
No details of data.
4. Sampling: Was the sampling strategy appropriate to address the aims?
Good Details (age/gender/race/context) of who was
studied and how they were recruited.
Why this group was targeted.
The sample size was justified for the study.
Response rates shown and explained.
Fair Sample size justified.
Most information given, but some missing.
Poor Sampling mentioned but few descriptive details.
Very poor No details of sample.
5. Data analysis: Was the description of the data analysis sufficiently
rigorous?
Good Clear description of how analysis was done.
Qualitative studies: Description of how themes
derived/respondent validation or triangulation.
Quantitative studies: Reasons for tests selected
hypothesis driven/numbers add up/statistical
significance discussed.
Table 1 Hawker tool description (Continued)
Fair Qualitative: Descriptive discussion of analysis.
Quantitative.
Poor Minimal details about analysis.
Very poor No discussion of analysis.
6. Ethics and bias: Have ethical issues been addressed, and
what has necessary ethical approval gained? Has the
relationship between researchers and participants been
adequately considered?
Good Ethics: Where necessary issues of confidentiality,
sensitivity, and consent were addressed.
Bias: Researcher was reflexive and/or aware of own
bias.
Fair Lip service was paid to above (i.e., these issues were
acknowledged).
Poor Brief mention of issues.
Very poor No mention of issues.
7. Results: Is there a clear statement of the findings?
Good Findings explicit, easy to understand, and in logical
progression.
Tables, if present, are explained in text.
Results relate directly to aims.
Sufficient data are presented to support findings.
Fair Findings mentioned but more explanation could
be given.
Data presented relate directly to results.
Poor Findings presented haphazardly, not explained,
and do not progress logically from results.
Very poor Findings not mentioned or do not relate to aims.
8. Transferability or generalizability: Are the findings of this study
transferable (generalizable) to a wider population?
Good Context and setting of the study is described
sufficiently to allow comparison with other
contexts and settings, plus high score in
Question 4 (sampling).
Fair Some context and setting described, but more
needed to replicate or compare the study with
others, PLUS fair score or higher in Question 4.
Poor Minimal description of context/setting.
Very poor No description of context/setting.
9. Implications and usefulness: How important are these findings to
policy and practice?
Good Contributes something new and/or different in
terms of understanding/insight or perspective.
Suggests ideas for further research.
Suggests implications for policy and/or practice.
Fair Two of the above (state what is missing in comments).
Poor Only one of the above.
Very poor None of the above.
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trajectory, the collaboration strategy and the effective-
ness of the models. In the following section, we confine
the presentation of the results to these categories.
Focus of intervention
All the included studies placed their focus on symptom
treatment. In particular, the objective of these interven-
tions was to improve physical symptoms (dyspnoea,
pain, constipation, nausea, vomiting, diarrhoea), emo-
tional symptoms (agitation, confusion, fear, delirium)
and to a lesser extent cognitive and social functioning
[20, 23, 28–31]. Nine studies focused on consulting
about end-of-life care decisions, advance care planning,
advice for coping with life-threatening disease and refer-
rals to specific care-settings. Five studies focused on the
training of the nurses and physicians involved in the
interventions. The various training programmes in-
cluded training of the staff to support patients over
the telephone [21], education on the symptoms of the
disease [28] and more general educational pro-
grammes for community professionals about palliative
care services [20, 24, 28].
Setting
The implementation of the models has taken place in a
variety of settings. In fact, most studies took place in
more than one setting with the majority focusing on in-
patient (11/14) and home care (9/11).
Timing of PC initiation
As regards the timing of the iniation of PC, three types
of studies were identified; those focusing on end-of-life
(11), on concurrent care setting (where PC care is pro-
vided alongside regular treatment)(3) and on both (4).
For the end-of-life setting, included patients typically
were expected to die within a range spanning from a few
weeks (2 weeks [26]) to few months (e.g. 2–9 months
[20]). For the concurrent care setting, eligible patients
were referred by clinicians as potentially benefiting from
PC assessments [29, 30]. Finally, for the combined
setting, various eligibility categories were identified. For
example, in [23] all patients with malignant disease inde-
pendent of the disease trajectory were eligible.
Composition of team
Three different team compositions were identified from
the included studies. The first type refers to teams com-
prising medical and nursing staff; 2 studies [23, 25]. The
second type concerns multidisciplinary teams compris-
ing different professions: general practitioners (GPs),
medical specialists, nurses and specialist nurses, psych-
iatrist and psychologists, health coordinators, adminis-
trative assistants, social workers, ambulance services,
dieticians and rarely occupational therapists and speech
therapists; 4 studies [21, 26, 33]. The third type corre-
sponds to multidisciplinary teams that additionally in-
volve PC experts. Besides being multidisciplinary, these
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Fig. 1 Flow diagram of study selection procedure
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Table 2 Characteristics of the included studies according to different disease categories
First Author, Year, Country Design Quality
Assessment
Model Outcome measurements Results/Effectiveness of the model
Cancer
Jordhøy et al. 2001,
(Norway) [20]
Cluster Randomised
Trial
33 Collaboration between palliative
medicine unit and community
service
HRQL*: physical, emotional
functioning, pain, psychological
distress. Place of death, hospital
utilisation.
There was no evidence of any impact
on the patients’ HRQL*. There was no
tendency in favour of any treatment
group on the main outcomes in
assessments that were made within
3 months before death.
Smeenk et al. 1998,
(The Netherlands) [21]
Quasi-experimental
study
31 Transmural home care programme:
collaboration primary care team
and supporting hospital care team.
Re-hospitalization, QoL*,
home death
Patients in the intervention group
underwent significantly less re-
hospitalization during the terminal
phase of their illness; the intervention
contributed significantly positive to the
patients physical QoL; A higher, not
significant percentage died at home.
Colombet et al. 2012,
(France) [22]
Case series study
nested in a cohort
30 Impact of oncologist’s awareness
of PC, clinical intervention of PCT*
and timing, multidisciplinary
decision-making.
Indicators: location of death,
number of ER* visits in last
month of life, chemotherapy
administration in last 14 days
of life.
58 patients died at home, 45 in an ICU
or ER, and 253 in an acute care hospital;
185 patients visited the ER* in last month
of life and 75 received chemotherapy in
last 14 days of life. OPM* independently
decreases the odds of receiving
chemotherapy in last 14 days of life.
Early PCT* intervention had no impact
on indicators, whereas OPM* reduced
the odds of persistent chemotherapy in
the last 14 days of life. Decision-making
with oncologists and the PC* team is
the most critical parameter for
improving EoLC*.
Schreml et al. 2000,
(Germany) [23]
Observational study 25 Integration of PC into regular
internal ward services in general
hospital.
Release of pain, respiratory
distress, dying in hospital, length
of hospital stay.
It is possible to integrate PC into a
regular internal medical ward, with
positive impact on recorded outcome
measures.
End-of-life (Liverpool Care Pathway)
Constantini et al. 2013,
(Italy) [24]
Cluster Randomised
Trial
34 LCP* for cancer patients dying
in hospital medical wards.
Quality of EoLC* from perspective
of bereaved family member;
communication between ward
staff and GPs* (VOICES)*.
Aspects of quality of EoLC* improved
(emotional, spiritual needs, self-efficacy);
slight improvement in communication,
no significant improvement in symptom
control.
Veerbeek et al. 2008,
(The Netherlands) [25]
Uncontrolled before
and after study
27 Effect of the LCP* on 3 health
care settings (hospital, nursing
home, home).
Comparison of level of
documentation, symptom burden
(EORTC QLQ-C30* questionnaire)
and aspects of communication
(VOICES)* before and after
introduction of LCP*.
Introduction of LCP* increased
documentation, decreased symptom
burden.
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Table 2 Characteristics of the included studies according to different disease categories (Continued)
Malignant and Non-malignant Disease
Grande et al. 2000, (UK) [26] Randomised controlled
trial
33 Cambridge Hospital at Home for
palliative care (CHAH).
Symptom control, adequacy of care,
likelihood of remaining at home in
their final 2 weeks, GP visits.
CHAH appeared to be associated with
better quality home care.
Vicente et al. 2010, (Spain) [27] Retrospective and
prospective cohort study
30 Influence of the Integrated Plan
of PC* of the Autonomous
Community of Madrid in the
medical activity of a hospital
based PC* unit.
Improvement in continuity of care,
coordination amongst assistant
bodies, increase in mean stay at
the PCU*, increase in number of
home deaths, etc.
PC home care improves continuity in
care of patients. Transfers to intermediate
stay care centers and deaths at home
increased. Median stay at the PCU*
decreased.
Dementia
Sampson et al. 2011, (UK) [28] Randomised controlled
trial
28 Pilot implementation of the
assessment of PC needs of
patients with severe dementia
and discussion with principal
carers to improve EoLC*.
Kessler Distress Scale, EQ-5D*,
Decision Conflicts Scale, Decision
Satisfaction Inventory, State Anger
Scale, Life Satisfaction Scale, Satisfaction
with EoLC*, Advanced Dementia
Scale (FAST Scale); Pain and distress
(the Abbey pain scale, the PACSLAC
and the Doloplus), delirium
(Confussion Assessment Method),
General unwillingness to address EoL*
issues. All carers were keen to receive
more information about EoL* issues in
dementia, found discussions very helpful.
Participation of clinical MD* team
facilitated integration of intervention
with the clinical service.
Multiple Scherosis
Higginson et al. 2009, (UK) [29] Randomised controlled
trial
36 Evaluation of cost-
effectiveness of a new PC
service for people with MS*.
Use of services, patient symptoms
(UNDS*, EDSS* and POS-8*), other
outcomes, caregiver burden (ZBI*).
Short-term PCT* was found to be cost-
effective, reducing inpatient and
community costs, caregiver burden
and possibly patient pain.
Edmonds et al. 2010, (UK) [30] Randomised controlled
trial
36 Evaluation of a novel PC
service.
MS Impact Scale, POS-8*, ZBI*,
Modified Lawton positivity
questionnaire.
MS patients who received PC* service
had improvements in 5 key symptoms
(pain, nausea, vomiting, mouth problems
and sleeping difficulties) on the POS and
improved informal caregiver wellbeing.
HIV/AIDS
Koffman et al. 1996, (UK) [31] A descriptive pilot
evaluation
23 Pilot evaluation of hospice
at home service for patients
with advanced HIV/AIDS; 24-h
terminal care.
STAS*, evaluating pain control,
other symptom control, patient/
family anxiety, patient/family insight
and communication between
patient and family, between
professionals, between professionals
and patient and family.
80 % died at home; STAS* showed
improvements in items ‘other symptoms
control’ and family insight.
Siouta
et
al.BM
C
Palliative
Care
 (2016) 15:56 
Page
7
of
16
Table 2 Characteristics of the included studies according to different disease categories (Continued)
Chronic Heart Failure
Pattenden et al. 2012, (UK) [32] Non-randomised pilot
evaluation
30 Collaborative PC* for advanced
heart failure.
Death in preferred place of care;
hospital admissions averted; costs
of medical procedures, inpatient
care and directs costs of intervention.
This pilot study provides tentative
evidence that a collaborative home-
based PC* service for patients with
advanced CHF may increase the
likelihood of death in place of choice
and reduce inpatient admissions.
Advanced Chronic Disease
Navarro et al., 2011, (Spain) [33] Observational, retrospective
and descriptive study
26 EoLC* of advanced chronic non-
cancer patients identified by
multidimensional evaluation
and interdisciplinary teamwork
in a medium and long term
hospital.
General data, terminal criteria,
diagnostic and prognostic
information, development of
advance directives, limiting levels
of effort care, times from admission,
risk of complicated bereavement.
Identification of advanced chronic non-
cancer patients and their needs by
interdisciplinary teamwork enabled
indication for PC soon after admission
and ensured appropriate care during
their stay.
Table 2 describes studies by each disease category according to author, year, country, design, quality assessment score, model, outcome measures and results/findings
Abbreviations: PC palliative care, QoL quality of life, PCT palliative care team, OPM onco-palliative meeting, EoL end of life, VOICES Views of Informal Carers – Evaluation of Services questionnaire, ER emergency room,
MDT multidisciplinary team, QoC quality of care, GSFCH Gold Standards Framework in Care Homes, LCP Liverpool Care Pathway, PCU palliative care unit, UNDS United Kingdom Neurological Disability Scale, EDSS
Expanded Disability Status Scale, POS-8 Palliative Care Outcome Scale, ZBI Zarit Carer Burden Inventory, ESH Hospital Support Team, EQ-5D EuroQOL five dimensions questionnaire, EoLC end of life care, MD medical
doctor, MS multiple sclerosis, STAS Support Team Assessment Schedule, ICU intensive care unit, CKD Chronic Kidney Disease
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Table 3 Characteristics of the models
First author Focus of the model Setting Time frame Disciplines represented Collaboration strategy
Cancer
Jordhoy et al. [20] treating, training, consulting Hospital, GP’s, nursing homes,
home care
end of life GP, community nurse, consultant
nurse, physician from PMU.
Model-responsible team meetingsa
Smeenk et al. [21] treating, training, consulting Hospital, primary care team concurrent, end of life Specialist nurse coordinator,
oncology ward nurses + medical
specialist, transmural home team
with nurses from hospital + day care.
Model-responsible team meetings,
protocol
Colombet et al. [22] treating, consulting Hospital concurrent, end of life 15 referral physicians: oncologists
who prescribe chemotherapy, of
whom 2 have been trained in PC
fundamentals. MDT: PCT and
oncology staff. PCT: PC specialists,
nurses, secretary assistant,
psychologist. Oncology staff:
physicians, nurses, head nurses,
social workers, psychologists,
secretaries.
Model-responsible team + additional
experts meetingb
Schreml, et al. [23] treating, training, consulting Hospital concurrent, end of life Physicians and nurses. Model-responsible team meetings
End-of-life (Liverpool Care Pathway)
Constantini et al. [24] treating, training Hospital end of life PCT: 2 physicians, 3 nurses, 2
psychologists.
protocol
LCP training: nurses and physicians
of the hospital wards.
Veerbeek et al. [25] treating Hospital, nursing home and
home
end of life Physicians and nurses. Model-responsible team meetings,
protocol
Malignant and Non-malignant Disease
Grande et al. [26] treating Home end of life Six qualified nurses, 2 nursing
auxiliaries, CHAH coordinator,
agency nursing care.
Model-responsible team meetings
Vicente et al.[27] treating Hospital, home end of life PC home team as an MDT
comprised by physicians, nurses,
nurse assistants, and administrative
assistants, social workes, psychologists.
Model-responsible team meetings
Dementia
Sampson et al. [28] treating, training, consulting Hospital, home end of life Senior nurse experienced in dementia
and trained in PC; clinical MDT.
Model-responsible team meetings
Multiple Sclerosis
Higginson et al. [29] treating, consulting Home, hospital outpatient
clinic, care homes, hospital
concurrent Part-time PC medicine consultant, 1
part-time clinical nurse specialist, 1
administrator, 1 psychosocial worker.
Model-responsible team meetings
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Table 3 Characteristics of the models (Continued)
Edmonds et al. [30] treating, consulting Home, hospital outpatient
clinics, care homes, hospital
concurrent Part-time consultant in PC Medicine
with specialist interest in neurological
conditions, part-time clinical nurse
specialist, full time administrator.
Model-responsible team + additional
experts meeting
HIV/AIDS
Koffman et al. [31] treating, consulting Hospice, home end of life Nurses trained in PC; bank nurses for
night-sitting; 2 PC medicine consultants.
Model-responsible team + additional
experts meeting
Chronic Heart Failure
Pattenden et al. [32] treating, consulting Homes, hospice, ‘care of
the elderly’ wards
concurrent, end of life Heart Failure nurse specialists, MCN
nurses, MCN health care assistants,
cardiology, ‘care for the elderly’
consultants, district nurses, GPs.
Model-responsible team + additional
experts meeting, protocol
Advanced Chronic Disease
Navarro et al. [33] treating Hospital concurrent The MDT consists of physicians, head
nurse, ward nurses, auxiliary nurses,
collaborating with a dietician,
psychologist, social worker,
rehabilitation physician, physiotherapist,
occupational therapist and speech
therapist.
Model-responsible team + additional
experts meeting
Table 3 describes five characteristics of the included studies: the focus of the model, the setting, the time frame of the model, the functions represented, and collaboration strategy involved
PC palliative care, GP general practitioner, PMU palliative medicine unit, PCT palliative care team, MDT multidisciplinary team, LCP Liverpool Care Pathway, MNC Marie Curie Cancer Care, CHAH Cambridge hospital at
home service, ESAD Home Care Support Team, MDM multidisciplinary meetings
ameetings of the team that is involved in the implementation of the model
bmeetings between the team responsible for the implementation of the model and other disciplines involved in the treatment of the patient
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teams also have PC physicians, PC nurses and PC psy-
chologists; 8 studies [22, 24, 31].
Collaboration strategy
The collaboration strategy refers to the ways that the
represented disciplines cooperate and assess emerging
issues. As shown in Table 3, the included studies employ
three different collaboration strategies and their combi-
nations: i) meetings of the team that is involved in the
implementation of the model (model-responsible team)
[20, 21, 23–28], ii) meetings between the model-respon-
sible team together with experts from other disci-
plines involved in the treatment of the patient [22,
29, 31–33], iii) utilization of predefined protocols [21,
24, 25, 32]. It is important to note that the collabor-
ation is not necessarily related to the composition of
the team. For example, a model-responsible team may
be multi-disciplinary but still base its decisions on
meetings where additional disciplines are represented.
In other words, the principal difference between (i)
and (ii) is the participation of experts that are not
directly related to the implementation of the model
in question on a frequent basis.
Effectiveness of the model
As regards effectiveness, all but one study [20], showed
positive outcomes in terms of better symptom control
and better quality of life, better communication between
personnel, patients and caregiver, more deaths at the pa-
tients’ homes and more cost-effective care. However, this
result should be interpreted with care given the variabil-
ity in the design of the interventions, some of which
were not RCTs and therefore of lower quality.
Importantly, even within RCTs, that constitute the
most robust design, further comparisons between the
results are cumbersome to perform. This is because
discrepancies are observed both in the outcome mea-
sures and in the tools employed for their assessment.
For example, as regards the evaluation of symptom
management, some of the studies used the European
Organization for Research and Treatment of Cancer
guidelines (EORTC QLQ-C30) questionnaire [24, 25, 34],
whereas others employed the United Kingdom Neuro-
logical Disability Scale (UNDS) [35], the Expanded
Disability Status Scale (EDSS) [36], the Palliative Care
Outcome Scale (POS-8) [37] and the Support Team
Assessment Schedule (STAS) [29–31, 38] or the
Abbey pain scale [39], the PACSLAC [40] and the
Doloplus [28, 41]. Also, communication aspects were
assessed via the Views of Informal Carers-Evaluation
of Services (VOICES) [42] tool [24, 25]. Further, care-
givers’ burden was measured with the help of the
Zarit Carer Burden Inventory (ZBI) [43], [29, 30].
Finally, stressful events were assessed via the Impact
of Event Scale (IES) questionnaire [44].
Discussion
We reviewed existing literature on evidence-based
models for integrated PC in patients with cancer or
chronic disease in Europe. Since the focus of the
present study was on the effectiveness of existing
models, only specific designs were considered as
eligible e.g. RCTs, cohort studies, etc. whereas others,
such as theoretical studies, audits, etc., were explicitly
excluded. In addition, in order to exclude empirical
studies that were conducted with low-quality stan-
dards, the numerical tool of Hawker et al. [17] was
employed for the assessment of the methodological
rigour. In this respect, only those studies that scored
at least 60 % in this tool were eligible.
The database search resulted in 14 empirical studies
that fulfilled the inclusion criteria. According to our
findings, there are only a few models of integrated PC in
Europe whilst the geographic distribution of the origin
of these interventions is imbalanced, with 6 out of 14
studies coming from the UK.
Only 6 out the 14 studies were RCTs whilst the
remaining employed different designs, e.g. observational
studies. However, as mentioned above, studies employ-
ing a different design for their assessment scored highly
on Hawker’s tool as well. Consequently, such non-RCT
studies can provide valuable insight into the strengths
and weaknesses of extant studies that has to be taken
into consideration if a complete description of the
current state-of-the-art is targeted, as is the case of the
present study.
Even though the included studies employ different
outcome measures and a direct comparison is not
possible, the effectiveness of the models (as assessed by
the outcome measures) was confirmed in 13 out of 14
studies. In particular, as mentioned above, the positive
impact typically involves better symptom control, higher
quality of life, less caregiver burden, improvement in
continuity and coordination of care, fewer hospital ad-
missions, patients dying more frequently at home, and
improved cost-effectiveness. Even though only 6 out of
14 studies were RCTs, and thus the results of the assess-
ments for the remaining studies should be treated with
care, the positive outcomes still add to the growing bulk
of evidence corroborating the effectiveness of both usual
and integrated PC on the improvement of the quality of
life of patients with life-threatening disease [4–8].
We now shift to the development of a framework of
integrated PC that could serve as a first step towards the
development of a generic model for both malignant and
non-malignant disease. Although the included studies
suggest practices that are in concordance with existing
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recommendations and empirical findings, no study pre-
sents an intervention that is optimal in all aspects. Con-
sequently, the generic framework that we propose is
based on a selective combination of the strengths of the
included interventions alongside a critical evaluation of
their weaknesses and shortcomings. First, we present the
aspects of the generic framework and subsequently we
rationalize our choice and motivations.
This generic framework consists of the following aspects.
 Focus of intervention: The focus of intervention
will be placed on symptom treatment, consulting
of patients/family and training of the personnel.
 Setting: The design of the framework is such that it
can be applied to every care setting.
 Timing of intervention: The intervention can be
initiated throughout the disease trajectory either
concurrently or in the end-of-life.
 Composition of team: The framework requires a
multidisciplinary team with members that are
trained in the delivery of PC. This team can consist
of GPs, physician specialists, nurses and specialist
nurses, psychologists, social workers and
administrative assistants.
 Collaboration strategy: The collaboration strategy,
which refers to the ways that the represented
disciplines cooperate and assess emerging issues,
should be based on the involvement of the
multidisciplinary team and its meetings and the
utilization of protocols.
The proposed framework has a threefold focus:
treatment, consulting and training. In our context of
integrated PC, treatment corresponds to the allevi-
ation of the physical (dyspnoea, pain, constipation,
nausea, vomiting, diarrhoea) and psychological symp-
toms (agitation, confusion, fear, delirium). On the
other hand, consulting refers to discussions and com-
munications over treatment options and at a later
stage to end-of-life care decisions. Moreover wishes,
desires and needs of the patients can be taken into
account as part of this advance care planning. Train-
ing involves the education of nurses, physicians and
other related health care providers involved in the in-
terventions. Training programmes can be very diverse,
however, their principal focus should be on PC, its
benefits and its provision.
The benefits of focusing on treatment are apparent,
however, the benefits of the remaining two aspects
are also well documented. As regards consulting, PC
typically involves difficult medical and ethical decision
making [4–8] for patients and their (in)formal care-
givers. Importantly, the same studies assert that the
burden associated with this decision making can be
ameliorated with the assistance of trained PC staff through
systematic consulting and informative discussions.
By contrast, regarding training, we first note that the
generic framework should be utilized with extreme cau-
tion because these suggestions may need to be tailored
to the specific situation. In other words, this framework
pertains to assist PC teams in their planning and imple-
mentation of PC strategies and not to provide black-box
solutions. In this respect, it should be highlighted that
the improper application of generic frameworks, and in
fact of every integrated PC framework, can jeopardize
the effectiveness of the employed PC practices. A not-
able example is the case of the Liverpool Care Pathway
(LCP) [45], which has been sometimes erroneously
employed, leading to poor outcomes and has in turn
been used as an excuse for poor quality care [46, 47].
Public outcry from the poor implementation of the LCP
led the UK government to stop the use of the LCP.
Recent studies explicitly state that there is a correl-
ation between the successful implementation of the
LCP and the training of the staff [48]. Importantly,
this constitutes a characteristic of integrated PC in
general [49–51]. For this reason, future efforts should
explicitly foster the educational aspect of the profes-
sional members.
The choice of the timing of the intervention and thus
the referral criteria is a contentious topic in the litera-
ture of PC. Historically, PC studies focusing on cancer
opted for an end-of-life time frame based on the premise
that once cancer reaches the terminal phase, the disease
trajectory declines rapidly so that end-of-life prognoses
can be fairly accurate [52, 53]; still, prognosis in cancer
is frequently over-optimistic [54]. However, early inte-
grated PC is increasingly supported by various studies,
because it has been documented to improve quality of
life in the last days and increase survival [4].
Moreover, end-of-life prognosis for non-malignant dis-
ease is problematic. For example, the typical trajectory
of Chronic Heart Failure (CHF) consists of acute crises
or exacerbations followed by elongated periods of stabil-
ity. At the same time, CHF patients are in high risk of
sudden death [55]. Consequently, for non-malignant dis-
ease, an end-of-life frame is cumbersome to realise and
a concurrent time frame of the initiation of PC is
deemed more appropriate [56]. On the other hand, there
is a growing number of studies supporting the decoup-
ling of the initiation of PC from the traditional end-of-
life time frame and the shift to the early integration of
PC in the disease trajectory [57–61].
According to our definition of integrated PC, the
timing of the initiation of PC care is not determined so
that models that focused on either concurrent PC or
end-of-life care were eligible. Despite the fact that, as
mentioned above, end-of-life care in patients with non-
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malignant disease is difficult to realise in practice, this is
not reflected in our results since representatives of both
categories are included for patients with either malig-
nant or non-malignant disease. As a consequence, our
generic framework necessarily employs a diverse number
of timings, ranging from concurrent to end-of-life. This
is not without implications as offering a spectrum of op-
tions, over a uniquely defined one, implies that the final
choice falls within the jurisdiction of the involved teams.
In turn, this might lead to significantly diverse practices
and, therefore, impede the benefits associated with PC.
Future studies should thus focus on the convergence of
opinions on the timing of PC so that ideally a standard-
ized recommendation is crafted.
In the proposed generic framework, the involved team
should be multidisciplinary in nature and involve experts
from different fields. Functionality of multidisciplinary
teams may be impeded by ambiguity of the distributed
roles, conflicts between the team members, communica-
tion problems and issues related to leadership [62, 63].
However, extant studies in PC for patients with both
malignant and non-malignant disease support the results
of this study showing that multidisciplinary teams
(MDTs) lead to better results when compared to uni-
disciplinary ones because they enhance continuity of
care, evidence-based decision making, ACP and high
quality care delivery [4, 64–66].
As the integration of PC requires bringing together
specialists from different backgrounds and their well-
orchestrated coordination, the development of proto-
cols that quantify their collaboration is imperative for
the successful implementation of PC. As mentioned
in the Results section, the included studies employ
miscellaneous collaboration strategies consisting of
distinct components: collaboration between the team
members (intra-team collaboration), multidisciplinary
team meetings and protocols. The intra-team collab-
oration, which constitutes the only common compo-
nent of all studies, is important because it assures the
efficient implementation of the PC strategy. Further,
for the aforementioned reasons multidisciplinary team
meetings are also important for enhancing the con-
tinuity of care. Lastly, protocols have compelling ad-
vantages because they provide a clear guide for the
next steps to be undertaken [67]. Since none of these
components are redundant and our results show that
they are complementary to each other in our generic
framework, we propose to employ a strategy based on
a combination of these.
Having addressed all the components of this generic
framework, a comment on the implications that this
framework has on the recommendations of the WHO
[1] is in order. Overall, the proposed framework accords
very well with the definition of PC provided by the
WHO, however, two important differences are identified.
First, the proposed framework highlights the training of
the healthcare providers, which is essential for the suc-
cessful implementation of integrated PC; this is not the
case of the WHO definition where training is absent.
Second, although WHO recognizes the need for employ-
ing a team approach no explicit reference on multidisci-
plinarity is made. By contrast, the proposed framework
emphasizes the importance of utilizing PC teams the
members of which come from various backgrounds.
Finally, it is interesting to juxtapose the timings of PC.
As mentioned above, due to the fact that the InSup-C
definition of integrated PC does not comment on the
timing, the proposed framework offers a multitude of
timings; from concurrent to end-of-life. The definition
of WHO states that PC “is applicable early in the course
of illness, in conjunction with other therapies that are
intended to prolong life…”. However, as stated, this
phrase does not explicitly promote early integration but
rather on its range of applicability. In other words, the
WHO definition does not narrow down the timing of
PC to concurrent but rather expends to a spectrum of
option in a manner similar to the proposed framework.
Consequently, if attention has to be shifted to a concur-
rent timing, this should be explicitly reflected in the cor-
responding definitions.
Additional information may be drawn by comparing
the five aspects of the generic framework against indica-
tors for integrated PC. Such sets of indicators do exist in
the literature, however, they correspond to PC in pa-
tients with cancer. Still, since cancer also pertains to the
present such a comparison is fruitful. A recent system-
atic review provided a set of 38 indicators for integrated
PC in oncology [68]. These indicators were grouped into
five groups namely: structure of clinical programs, pro-
cesses of clinical programs, education, research and ad-
ministration. The same grouping was employed in the
subsequent study [68], where a set of 43 indicators (13
major and 30 minor) was proposed based on a consen-
sus of experts. Interestingly, with the exception of re-
search, the generic framework, and the models that has
been composed from, satisfies the majority of these indi-
cators for both studies.
Study limitations
The first limitation of this study concerns the broad-
ness of the topic under investigation. Integrated PC
in cancer and non-cancer patients and without time
specification is a very large area and requires a quite
generic search strategy. Moreover, in view of this
broadness, we were confronted with a substantially
heterogeneous set of results that could only be
accessed through a qualitative description.
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The search strategy employed was developed upon
consensus between the PC experts involved in the pro-
ject meetings. However, a unanimously agreed definition
for integrated PC does not currently exist. Consequently,
even though our strategy is broad, some evidence might
have been missed due to the keywords used for the
search strategy.
A third limitation concerns the choice of the languages
of the included studies. The present study is confined to
studies published in Dutch, English, French, German,
Hungarian and Spanish, that were the languages that the
project partners were knowledgeable of. It is, therefore,
possible that studies published in other EU languages
are available and not included [69].
Finally, we stress that the generic framework proposed
herein has been based on models for patients with can-
cer and non-cancer disease. Its validity, therefore, is for-
mally limited to these particular diseases. Although
extrapolations to other types of life-threatening disease
are tempting, further study in this direction is clearly
needed. Also even though the proposed framework aims
to be generic, one has to acknowledge limitations stem-
ming from differences between healthcare systems, cul-
tural and geographic factors and funding levels.
Moreover, the preponderance of UK studies in this
review should not go unnoticed. This is further sup-
ported by [70] who argue that generic models have to
be flexible enough to be tailored to different settings;
as a consequence, their recommendations should not
be extremely stringent.
Conclusions
This is the first qualitative systematic literature review
of models on integrated Palliative Care (PC) in
patients with malignant and non-malignant disease in
Europe. It represents the combined effort of an inter-
national consortium of six partners in six different
European countries (Belgium, Germany, Hungary,
Spain, The Netherlands and United Kingdom).
Based on the results, we have proposed a generic
framework for integrated PC in patients with cancer and
chronic disease. The proposed generic identifies the im-
portance of employing a PC-trained multidisciplinary
team and of having a threefold focus: on treatment, con-
sulting and training. Each component of our framework
has been already empirically assessed, however, the over-
all framework has not. Although one could extrapolate
the existing empirical evidence in favour of our frame-
work’s efficacy, we believe that an empirical study for
the framework as a whole should carried. Such a study
not only will provide empirical evidence on the frame-
work’s efficacy but will also shed light on possible weak-
nesses that can be only traced post-implementation.
Additionally, it would be interesting to conduct the same
systematic review in non-European countries and per-
formed a comparative analysis in a worldwide scale.
Appendix
In this appendix we present the search terms that were
used for our search strategy.
“(hospices OR supportive care OR supportive care* OR
end of life care* OR palliative* OR palliative care [MeSH
Terms] OR hospice* OR terminal care* OR coordinated
care* OR integrated care* OR transmural care* OR pro-
gressive patient care*) AND (“end stage disease” OR end
stage disease* OR dying OR death [MeSH Terms] OR
Chronic disease [MeSH Terms] OR Chronic disease* OR
terminally ill* OR terminally ill [MeSH Terms] OR can-
cer) AND (care pathway* OR care pathway OR pathway*
OR patient transfer* OR patient transfer OR patient care
team* OR managed care program* OR continuity of pa-
tient care OR patient care management OR patient care
plan* OR patient care planning OR illness trajectory OR
“advance care planning” OR advance care planning OR
delivery of health care OR models of care OR model of
care OR model organizational OR models organizational
OR organizational model* OR guideline*) NOT ((birth)
OR child) OR pediatrics)) NOT ((animals[mh] NOT
humans[mh])) Filters: Publication date from 1995/01/01
to 2013/12/31”.
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